Human Genome Sciences News Today

Still cant [inaudible] why the looting, why the violence . Angry about the way were being viewed as not people. A recent poll finds most americans believe Race Relations in this country are bad. More than 50 of whites think so. More than twothirds of blacks feel this way. People are angry. Where we go from here, i dont know. Theres one race, the human race. Weve been together and apart more than 239 years, part of this great experiment, the United States of america. [cheers and applause] there h...

Dan here is how the evening will work. I will give you a brief overview of how the evening will work, a few minutes on the theory of direct action and questions to think about, then i will turn it over to the panelists. Each of the five has been asked to speak for more not more than 12 minutes. I will give the meantime check toward the end give them a time check toward the and. We are going to talk about and the larger movement, what works, what doesnt, the concerns raised in the movement and th...

Director/Board Member at Diligent Corp., Discover Betsy Atkins's known position history, network and 100 relationships. Find out about his known public assets.

-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-

Gene therapy made significant breakthroughs between 2000 and the 2010s, marking a golden era in medical history.

Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and...

/PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of...

Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenue guidance for 2023.

Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel,...

Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call.